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Introduction
Previous studies have demonstrated that the incidence
rate of cardiovascular disease in premenopausal women
is lower than that in either postmenopausal women 
or men1,2. This has been related to a protective effect
exerted by ovarian hormones against cardiovascular
disease. However, recent large, well-designed, random-
ized placebo-controlled clinical trials have reported
that postmenopausal hormone replacement therapy
(HRT) increases3,4 or has no significant effect on stroke
risk5. These conflicting results have led to the recom-
mendation that there are important differences on the
effect on stroke risk between physiologic endogenous
estrogens and exogenous hormones administered after
menopause. In addition, several prospective studies
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SUMMARY
Background: Results from previous studies regarding relationships between age at menarche and cardiovascular
disease remain controversial. This study investigated the association between endogenous estrogen exposure
and ischemic stroke risk.
Methods: A total of 189 ischemic stroke patients and 192 age-matched healthy postmenopausal women were
recruited. Age at menarche and menopause and risk factors of ischemic stroke were recorded through structured
questionnaires by well-trained research assistants. Lifetime estrogen exposure was calculated as the number of
years between age of menarche and menopause.
Results: Study subjects with a history of hypertension and diabetes mellitus have a 2.8- and 6.2-fold increased
risk for ischemic stroke, respectively. In addition, study subjects with waist circumferences ≥ 80 cm also have a
2.6-fold increased risk of ischemic stroke. Conversely, subjects who experienced menarche at an early age may
have a significantly decreased risk of 0.3-fold for ischemic stroke. Moreover, there was a significant and joint
protective effect for study subjects without any risk factors of ischemic stroke, including a history of hypertension
and diabetes mellitus, late age at menarche, and shorter lifetime estrogen exposure; these subjects were found
to have the lowest risk (0.03-fold) for the development of ischemic stroke.
Conclusion: Our study provides strong evidence that a significant joint protective effect was observed for
patients who undergo early menarche, have longer estrogen exposure and no history of hypertension or diabetes
mellitus on the risk of ischemic stroke. [International Journal of Gerontology 2010; 4(1): 16–22]
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have indicated that women who experience natural
menopause at an early age have a higher risk of coro-
nary heart disease6–9. However, the relationship with
earlier age at menarche and cardiovascular disease is
not clear10–13. Therefore, we hypothesized that if endog-
enous estrogens were protective, indicators of high
estrogen exposure leading to early menarche, late meno-
pause and a longer estrogen exposure would be asso-
ciated with a lower risk of ischemic stroke. Hence, we
conducted a case-control study to examine the above
estrogen exposure indicators in relation to the risk of
ischemic stroke.
Subjects and Methods
Female acute ischemic stroke patients who had suffered
at least one episode of symptomatic ischemic stroke 
or transient ischemic attack were recruited from Chi
Mei Medical Center, Lotung Poh-Ai Hospital, Wan-Fang
Hospital, and Taipei Medical University Hospital. Ischemic
stroke was defined as a recent infarct in the clinically
relevant area of the brain on a computed tomography
or magnetic resonance imaging brain scan performed
within 10 days of the event. Controls were age-matched
women who had not suffered a stroke. Most were re-
cruited from a community-based prospective study in
Taipei, which was described in a previous study14. Some
were selected from subjects who attended the annual
health examinations of the health center at Taipei
Medical University Hospital. All study subjects were
postmenopausal women. Informed consent for partici-
pants in the study was obtained from all cases as well as
controls. The study was approved by the ethics commit-
tees of the participating hospitals and Taipei Medical
University on the understanding that all data would
be coded and patient anonymity would be guaranteed.
There were 189 ischemic stroke patients and 192 age-
matched healthy controls consecutively recruited in
this study.
Data collection and risk factor definition
Information concerning menstrual history, including
menstrual status and regularity, age at menarche and
menopause, was collected through a structured ques-
tionnaire by well-trained research assistants. The de-
finition of menopause was the age at the definitive
cessation of menstruation, whether natural or resulting
from oophorectomy. The duration of estrogenic lifetime
was calculated as the number of years between age 
of menarche and menopause. The history of oral con-
traceptive or HRT use was recorded. Each participant
was asked how often she had consumed soybean-
containing food, such as tofu, miso soup and beans,
on average per week. Isoflavone intake was determined
in the same manner. Body mass index was defined as
the individual’s body weight divided by square of their
height (kilogram per squared meter). The definition 
of hypertension and diabetes mellitus were based on
disease history from the questionnaires among pa-
tients. For controls, hypertension and diabetes melli-
tus were classified according to their blood pressure
and fasting glucose level in the serum. Hypertensive
subjects were diagnosed if their systolic blood pres-
sure was ≥ 140 mmHg or diastolic blood pressure was
≥ 90 mmHg or if they were taking an antihypertensive
drug. Diabetes mellitus was defined as fasting serum
glucose level of ≥ 126 mg/dL or a history of oral hypo-
glycemic agent use or insulin injection.
Statistical analysis
Quantitative data were compared between cases and
controls by the unpaired Student t test and expressed
as mean± standard deviation. Categorical variables were
assessed using the χ2 test and were expressed as fre-
quency and percentage. A logistic regression model was
performed to estimate the odd ratio (OR) and 95% con-
fidence interval (CI). Stepwise logistic regression analysis
was employed to determined potential risk factors for
ischemic stroke. We further evaluated the combined
effect of late menarche age (>15 years), shorter lifetime
estrogen exposure (≤ 36 years) and history of hyperten-
sion or diabetes mellitus on the ischemic stroke risk and,
therefore, classified the study subjects into eight groups.
Statistical differences were considered significant at
p<0.05. SAS version 9.1 statistical software (SAS Institute
Inc., Cary, NC, USA) was used for statistical analysis.
Results
The mean age of participants was 66.4 ± 9.5 years for
cases and 64.9 ± 8.9 years for controls (p > 0.05). Table 1
shows the frequency distribution and the ORs with the
95% CIs for the traditional risk factors in the 189 patients
and 192 controls. An education level greater than 12
years was more frequent in controls than in cases.
Diabetes mellitus and hypertension history were major
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risk factors with the strongest effects on risk of ischemic
stroke in this study, showing significant differences in
the age- and education-adjusted risks of 6.2- and 2.8-
fold, respectively. Obesity indicators, including body
mass index and waist circumference, also indicated dif-
ferences between cases and controls. A significant dif-
ference on the risk of ischemic stroke was observed for
waist circumference (OR, 2.6; 95% CI, 1.6–4.5). However,
the effect of body mass index on ischemic stroke risk
was nonsignificant after adjusting for age and education
level. Hyperlipidemia and cigarette smoking revealed
no evidence of an association with ischemic stroke in
these study subjects.
The relationship between the history of oral con-
traceptive use, HRT use, dietary intake of soybeans or
isoflavones and ischemic stroke are listed in Table 2.
After adjusting for age and education level, subjects
with an HRT history had significant decreased risk of
ischemic stroke. Compared with participants who have
an average dietary intake of soybeans < three times per
week, those who consumed soybeans ≥ three times per
week have a significantly decreased risk of ischemic
stroke (OR, 0.5; 95% CI, 0.2–0.8). A 0.5-fold decreased risk
of ischemic stroke was observed for those who have
intake of isoflavone ≥ three times per week, but the OR
did not reach statistical significance.
Table 3 summarizes the effects of estrogen exposure
indicators including age at menarche, age at meno-
pause, and the duration of lifetime estrogenic exposure
on the risk of ischemic stroke. Compared with those
study subjects whose menarche age was ≥ 16 years as a
reference group, menarche between the ages of 14 and
15 seemed to be related to a lower risk of ischemic
stroke and a significantly decreased risk was observed in
those whose menarche age was < 14 (OR, 0.3; 95% CI,
0.1–0.7). A significant trend test indicates that the ear-
lier menarche commenced, the lower the risk of is-
chemic stroke. Although late menopause age seemed
to be related to a lower risk of ischemic stroke, the ORs
of ischemic stroke risk among study subjects whose
menopause age ranged 49–50 years or >50 years were
not significant. However, a borderline significant trend
Table 1. Traditional risk factors and risk of ischemic stroke
Characteristics
Healthy controls Stroke patients 
OR (95% CI) OR* (95% CI)
(n = 192) (n = 189)
Education level, n (%), yr
≤ 12 62/164 (37.8) 140/160 (87.5) 1.0 1.0
≥ 13 102/164 (62.2) 20/160 (12.5) 0.1 (0.05–0.2)† 0.1 (0.1–0.2)†
Hyperlipidemia, n (%)
No 96/185 (51.9) 79/155 (51.0) 1.0 1.0
Yes 89/185 (48.1) 76/155 (49.0) 1.0 (0.7–1.6) 1.1 (0.6–1.9)
Diabetes mellitus, n (%)
No 168/189 (88.9) 81/158 (51.3) 1.0 1.0
Yes 21/189 (11.1) 77/158 (48.7) 8.0 (4.6–14.0)† 6.2 (3.2–11.9)†
Hypertension, n (%)
No 99 (51.6) 43/179 (24.0) 1.0 1.0
Yes 93 (48.4) 136/179 (76.0) 3.4 (2.2–5.3)† 2.8 (1.6–4.9)†
Cigarette smoking, n (%)
No 181 (94.3) 144/158 (91.1) 1.0 1.0
Yes 11 (5.7) 14/158 (8.9) 1.6 (0.7–3.6) 1.4 (0.5–3.7)
BMI, n (%)
≤ 27 127/159 (79.9) 107/162 (66.0) 1.0 1.0
> 27 32/159 (20.1) 55/162 (34.0) 2.0 (1.2–3.4)‡ 1.8 (1.0–3.2)
Waist circumference, n (%)
< 80 125 (65.1) 73 (38.6) 1.0 1.0
≥ 80 67 (34.9) 116 (61.4) 3.0 (2.0–4.5)† 2.6 (1.6–4.5)†
*Adjustment for age and education level; †p < 0.001; ‡p < 0.01. OR = odds ratio; CI = confidence interval; BMI = body mass index.
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test was observed (p = 0.09). A longer estrogenic expo-
sure was associated with a lower risk of stroke, i.e., the
lowest OR of risk of ischemic was obtained through
study subjects with the longest duration of estrogen
exposure. However, the association was not significant
after adjusting for age and education level.
Factors significantly associated with an increased risk
of ischemic stroke provided by the stepwise logistic
regression model after adjustment for potential covari-
ates are presented in Table 4. Consequently, both an
age at menarche <14 years and an education level >13
years were independent factors for a decreased risk of
Table 2. Relationship between history of oral contraceptive use, hormone replacement therapy (HRT) use, dietary intake of
soybeans or isoflavone and ischemic stroke
Healthy controls Stroke patients OR OR* 
(n = 192) (n = 189) (95% CI) (95% CI)
History of oral contraceptive, n (%)
No 147/191 (77.0) 146/177 (82.5) 1.0 1.0
Yes 44/191 (23.0) 31/177 (17.5) 0.7 (0.4–1.2) 0.8 (0.4–1.6)
History of HRT, n (%)
No 131/189 (69.3) 153/176 (86.9) 1.0 1.0
Yes 58/189 (30.7) 23/176 (13.1) 0.3 (0.2–0.6)† 0.4 (0.2–0.7)‡
Intake of soybeans (per week), n (%)
< three times 123/191 (64.4) 139/174 (79.9) 1.0 1.0
≥ three times 68/191 (35.6) 35/174 (20.1) 0.5 (0.3–0.7)‡ 0.5 (0.2–0.8)§
Intake of isoflavone (per week), n (%)
< three times 177/191 (92.7) 169/174 (97.1) 1.0 1.0
≥ three times 14/191 (7.3) 5/174 (2.9) 0.4 (0.1–1.1)|| 0.5 (0.2–1.8)
*Adjustment for age and education level; †p < 0.001; ‡p < 0.01; §p < 0.05; 0.05 < p < 0.1. OR = odds ratio; CI = confidence interval.
Table 3. Effects of age at menarche, age at menopause, and lifetime estrogen exposure on risk of ischemic stroke
Healthy controls (n = 192) Stroke patients (n = 189) OR (95% CI) OR* (95% CI)
Age at menarche, n (%), yr
≥ 16 47/179 (26.3) 68/125 (54.4) 1.0† 1.0†
14–15 59/179 (33.0) 44/125 (35.2) 0.5 (0.3–0.9)‡ 0.6 (0.3–1.1)
< 14 73/179 (40.8) 13/125 (10.4) 0.1 (0.1–0.2)§ 0.3 (0.1–0.7)||
Age at menopause, n (%), yr
≤ 48 50/170 (29.4) 46/139 (33.1) 1.0 1.0¶
49–50 42/170 (24.7) 43/139 (30.9) 1.1 (0.6–2.0) 0.8 (0.4–1.8)
≥ 51 78/170 (45.9) 50/139 (36.0) 0.7 (0.4–1.2) 0.6 (0.3–1.1)
Lifetime estrogen exposure, n (%), yr
≤ 32 41/166 (24.7) 39/109 (35.8) 1.0† 1.0
33–36 50/166 (30.1) 38/109 (34.9) 0.8 (0.4–1.5) 0.6 (0.3–1.4)
≥ 37 75/166 (45.2) 32/109 (29.4) 0.4 (0.2–0.8)|| 0.5 (0.2–1.1)
*Adjustment for age and education level; †p value for trend test < 0.05; ‡p < 0.05; §p < 0.001; p < 0.01; ¶p value for trend test: 0.05 < p < 0.1.
OR = odds ratio; CI = confidence interval.
Table 4. Stepwise logistic regression: odds ratios of risk 
factors associated with ischemic stroke after
adjustment for covariates
Odds ratio 95% CI
Education level > 13 yr 0.1 0.03–0.3*
Diabetes mellitus 3.4 1.3–8.8†
Waist circumference ≥ 80 cm 1.1 1.0–1.1*
Age at menarche < 14 yr 0.2 0.05–0.6‡
Intake of soybeans < three 3.2 1.1–9.2†
times per week
*p < 0.001; †p < 0.05; ‡p < 0.01. CI = confidence interval.
International Journal of Gerontology | March 2010 | Vol 4 | No 120
■ ■Y.C. Hsieh et al
ischemic stroke. Diabetes mellitus, waist circumference
≥ 80 cm, and dietary intake of soybeans < three times
per week were independently associated with increased
risk of ischemic stroke. A 58.76% of –2 log likelihood
implied that the model shown in Table 4 accounted for
more than half of the variance of ischemic stroke risk.
A joint effect on the risk of ischemic stroke
between three risk factors including history of hyper-
tension or diabetes mellitus, age at menarche > 15
years and lifetime estrogen exposure ≤ 36 years are
listed in the Figure. Compared with a reference group
that included subjects with all three risk factors men-
tioned above, those without any risk factors would
have the significantly lowest risk of ischemic stroke
(OR, 0.03; 95% CI, 0.003–0.2). A significantly decreased
risk of 0.1- and 0.4-fold for ischemic stroke was
observed among study subjects with one and two risk
factors, respectively. A significant trend test indicated
that study subjects with a fewer number of risk factors
would have the lower risk for suffering from an
ischemic stroke (p for trend, 0.0002).
Discussion
In this case-control study, early menarche was inde-
pendently associated with a lower risk of ischemic
stroke, after adjusting for risk factors of cardiovascu-
lar disease. In addition, late menopause and a longer
lifetime estrogen exposure also tended to be related
with a decreased risk of ischemic stroke. These find-
ings support the hypothesis proposed by previous
observational studies that exposure to endogenous
estrogens protects against ischemic stroke.
Since women who reach menarche at an early age
are exposed to endogenous estrogen for a longer period
than those who reach menarche at a later age, one
might expect the groups of menarche at an early age
to have a lower risk of cardiovascular disease. Many
studies in Western countries indicated an inverse rela-
tionship between early menarche and cardiovascular
disease15,16. However, the Japan Collaborative Cohort
study in Japan found that a late age at menarche was
prone to be associated with an increased risk of mor-
tality from stroke among total subjects aged 40–79
years. Nonetheless, the OR did not reach a significant
level10. This inconsistent result might be due to ethnic
differences. Many studies have gone on to show that
early menarche is associated with increased cardiovas-
cular disease because of increased body fatness in
childhood, and there are more obese adolescent girls 
in Western countries than in Asian countries including
Taiwan. Our study also found that increased age at
menopause and a longer lifetime estrogen exposure
had protective effects on a decreased risk of ischemic
stroke. This finding is consistent with those showing that
early menopause and a shorter estrogenic lifetime expo-
sure were correlated with a higher risk of mortality
from cardiovascular disease among American and
European women7,17,18. The reasons for the depletion of
estrogen itself may have a deleterious effect on the
development of atherosclerosis because of elevated
serum total or LDL-cholesterol levels19, endothelial
dysfunction20 and increased platelet aggregation21.
Hypertension, diabetes mellitus, obesity, and expo-
sure to cigarette smoke are well-documented and mod-
ifiable risk factors for ischemic stroke22. Our study also
showed that hypertension, diabetes mellitus, and obe-
sity were associated with ischemic stroke; however, cig-
arette smoking was not. This could be explained by the
very low prevalence of smoking among the women in
our study.
Reference
I
I
I
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II
II
III
1.0†Yes
Yes
Yes
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Yes
No
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or DM
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No
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Age at
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> 15 yr
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No
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No
No
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Lifetime
estrogen
exposure ≤ 36 yr
1.0
1.1 (0.2–4.8)
0.4 (0.2–0.9)‡
0.2 (0.1–0.5)§
0.2 (0.1–0.4)||
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0.1 (0.02–0.3)||
0.03 (0.003–0.2)||
OR* (95% CI) Group OR* (95% CI)
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Figure. Joint effect on risk of ischemic stroke between history of hypertension or diabetes mellitus, age at menarche, and
lifetime estrogen exposure. *Adjustment for age and education level; †p value for trend test < 0.05; ‡p < 0.05; §p < 0.01;
p < 0.001. DM = diabetes mellitus; OR = odds ratio; CI = confidence interval.
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To assess the joint effect of ischemic stroke for late
menarche age (> 15 years), shorter lifetime estrogen
exposure (≤ 36 years) and history of hypertension or
diabetes mellitus, we calculated the combined risk of
ischemic stroke for study subjects with different com-
binations of the three factors. Our study provided strong
evidence that the fewer risk factors the study subjects
have, the lower their risk of ischemic stroke, resulting
in a significant joint effect in the absence of these risk
factors by decreasing risk 85% (from 0.2- to 0.03-fold)
for ischemic stroke. As is the case in many studies, the
observed correlation here could be a chance finding.
Determining whether there is causal relationship be-
tween these risk factors and their effect on stroke
should be further confirmed by data derived from dif-
ferent and larger populations.
Previous observational studies have reported that
the use of HRT is associated with a reduced risk of
coronary heart disease23. A similar result was also found
in the present study. Although randomized clinical tri-
als demonstrated no advantage of HRT on the risk 
of coronary heart disease3–5, a potential benefit of es-
trogen therapy was found for young postmenopausal
women aged 50–59 years24. In our study, we found
that 82.2% of control subjects and 64.7% of cases used
HRT before 60 years of age. This might be the reason
why the use of HRT was related with a lower risk of is-
chemic stroke in our study.
Evidence is mounting that consumption of soy pro-
tein could lower blood cholesterol levels and may also
reduce the risk of cardiovascular disease25. Dietary soy-
beans with their high polyunsaturated fat, fiber, vitamin,
and mineral content combined with its low saturated fat
content may be beneficial to cardiovascular health26.
Soy-derived isoflavones have been associated with a
reduced risk of cerebral and myocardial infarctions27.
Our study found that a lower frequency of dietary intake
of soybeans was significantly associated with increased
ischemic stroke, but the effect of isoflavone intake was
not significant. This might have resulted from few sub-
jects who consumed isoflavones ≥ three times per week.
There were some potential limitations of this study.
First, it cannot be ruled out that misclassifications re-
garding the age at menarche and age at menopause
may have occurred as a result of study subjects’ recall
bias. However, we did try and prevent this by asking
subjects questions like what school grade they were in
when menarche occurred. In addition, we tried to pre-
empt such bias by excluding women who could not be
sure of their age at menarche. Furthermore, reproduc-
ibility and validity studies have indicated that most
women are able to report the age at menopause and
even the age at menarche with a high degree of accu-
racy28–30. Those studies also pointed out that data re-
garding reliability depend mainly on the subject’s age
and education. Although the education level was signif-
icantly higher in controls, the association between men-
strual factors and ischemic stroke remained consistent
when using stratification analysis by education level.
However, the controls recruited in our study were aged-
matched with cases, and education level was adjusted
in our study. The consequence of a non-differential
misclassification of recall bias might not influence the
results in our study.
Second, a larger sample size is needed to validate
the association between menstrual factors and ische-
mic stroke risk.
In conclusion, our study found that early menarche
was associated with a reduced risk of ischemic stroke,
which can be explained by a protective effect of endoge-
nous estrogen on the development of atherosclerosis.
A significant joint protective effect on the risk of is-
chemic stroke was also observed among study subjects
without risk factors such as hypertension and diabetes
mellitus, late age at menarche, and a shorter lifetime
exposure to estrogen.
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